This site is intended for health professionals only

Published on 2 February 2007

Share this story:
Twitter
LinkedIn

Drug approval in von Willebrand disease

teaser

Grifols has received approval from the FDA to market Alphanate (antihaemophilic factor/von Willebrand factor complex [human]) for the treatment of congenital von Willebrand disease (VWD) in connection with surgery or other invasive procedures.

The drug is indicated for the prevention and control of bleeding in patients with factor VIII deficiency. It is also indicted for surgical and/or invasive procedures in patients with VWD, except type 3 patients undergoing major surgery, in whom desmopressin is either ineffective or contraindicated.



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn